10-Q: Pharma-Bio Serv Q1 Net Income Rises Amid Revenue Dip

Pharma-Bio Serv, Inc. reported a significant increase in net income for the first quarter of fiscal year 2026 despite a slight decline in overall revenues, driven by improved gross profit margins and higher other income.

Summary

• Net income for the three months ended January 31, 2026, increased to $32,860, up from $8,536 in the prior year period.
• Total revenues decreased by approximately $0.2 million to $2.3 million for the quarter, compared to $2.47 million in the same period last year.
• Gross profit margin improved by 0.4 percentage points to 31.5% for the quarter.
• Cash and cash equivalents increased significantly to $5,763,618 as of January 31, 2026, from $3,379,212 at October 31, 2025.
• The company declared a cash dividend of $0.075 per common share, totaling $1,717,627, payable on or about March 20, 2026.
• The company repurchased 3,100 shares of common stock for $1,681 during the quarter under its ongoing repurchase program.
• The company is pursuing collection of a $6,717,431.69 judgment against Romark Global Pharma, LLC and affiliates, but cannot guarantee a successful outcome.
• Headquarters administrative operations transitioned to a virtual landscape following the lease expiration on December 31, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed report. While net income and cash flow from investing activities show strong improvement, the overall revenue decline and persistent operational loss, coupled with the uncertainty of collecting a significant legal judgment, temper enthusiasm.

Positives

• Net income significantly increased to $32,860 for the three months ended January 31, 2026, compared to $8,536 in the prior year.
• Gross profit margin improved by 0.4 percentage points, reaching 31.5% for the quarter.
• Other income, net, increased to $131,025, primarily due to higher interest income, foreign exchange settlement gains, and a gain on vehicle disposition.
• Cash and cash equivalents saw a substantial increase of $2,384,406 during the quarter, ending at $5,763,618.
• Net cash used in operating activities decreased to $(390,139) from $(429,486) in the prior year, indicating improved operational cash efficiency.
• The company successfully transitioned its headquarters administrative operations to a virtual landscape, aiming for more competitive service delivery.
• Management believes current working capital, operations, and cash flows are sufficient to fund anticipated expenses and long-term commitments for at least the next twelve months.

Negatives

• Total revenues decreased by approximately $0.2 million (7.1%) to $2.3 million for the three months ended January 31, 2026, compared to $2.47 million in the prior year.
• Revenue declines were noted in the European and US consulting markets, each decreasing by approximately $0.1 million.
• Loss from operations slightly widened to $(94,535) from $(92,191) in the prior year period.
• The company has an outstanding judgment of $6,717,431.69 against Romark Global Pharma, LLC and affiliates, but collection efforts have been unsuccessful so far, and a successful outcome cannot be guaranteed.
• A significant portion of revenues and accounts receivable are concentrated with a few major customers, posing a concentration risk.

Risks

• Regional or global conflicts, including war and economic sanctions between nations, may adversely affect future performance.
• Price inflation could negatively impact operations and profitability.
• Pandemics pose current and future challenges that may adversely affect future performance.
• Possible tax changes in jurisdictions where the company does business, including the new OBBBA provisions effective fiscal year 2027, could impact financial results.
• Bio-pharmaceutical industry consolidations and relocations may reduce demand for services.
• Trends in managing contract resources by customers could affect service opportunities.
• The company's ability to collect the $6,717,431.69 judgment against Romark Global Pharma, LLC and affiliates is uncertain, with no guarantee of a successful outcome.
• Concentration of revenues and accounts receivable with a few major customers (45.1% of segment revenues, 46.6% of global revenues, and 40.7% of accounts receivable from four customers) poses a significant risk if any of these relationships are disrupted.
• The Puerto Rico tax grant (Act No. 73) expired on October 31, 2024, and while an extension has been requested, there is no status update, and its non-renewal could impact tax liabilities.

Future Outlook

Management anticipates that future profitability and liquidity will depend on the impact of local and global economic conditions, including regional conflicts, price inflation, pandemics, changes in tax laws (like OBBBA effective FY22027), industry consolidations, and the company's ability to adapt to industry trends and seek new service opportunities. The company expects to maintain its service level competitively through its new virtual headquarters model. While an extension for the Puerto Rico tax grant is pending, management does not foresee significant concerns with its approval.

Management Comments

• "We actively operate in Puerto Rico, the United States, Europe and, to a lesser extent, Brazil and pursue to further expand these markets by strengthening our business development infrastructure and by constantly realigning our business strategies as new opportunities and challenges arise."
• "We consider our core business to be Food and Drug Administration (FDA) and international agencies regulatory compliance consulting related services."
• "As of the date of this filing, we have not received a status update from PRIDCO for that tax grant request. However, we do not anticipate any significant concerns with the Grant approval."
• "The move [to a virtual headquarters] will enable us to maintain the same level of service in a more competitive manner."
• "Management believes that based on the current level of working capital, operations and cash flows from operations, and the collectability of high-quality customer receivables are sufficient to fund anticipated expenses and satisfy other possible long-term contractual commitments for and beyond the next twelve months."
• "Management is not aware of any other trends or events likely to have a material adverse effect on liquidity or its financial statements."

Industry Context

StockSavvy.ai notes that Pharma-Bio Serv operates in a specialized niche within the broader life sciences consulting sector, focusing on compliance and technology transfer. The reported revenue decline in Europe and the US, while offset by growth in Puerto Rico, suggests regional variations in demand for compliance services. The industry faces ongoing challenges from global economic conditions, regulatory changes (like OBBBA impacting foreign earnings), and consolidation within the bio-pharmaceutical sector, which could influence client demand and pricing power. The company's shift to a virtual headquarters aligns with broader trends in professional services to reduce overhead and enhance flexibility.

Comparison to Industry Standards

• NA

Legal Proceedings

• The company's subsidiaries (Pharma-Bio Serv PR, Inc., Pharma Serv, Inc., and Scienza Labs, Inc.) filed a breach of contract and money collection complaint against Romark Global Pharma, LLC, Romark Properties, LLC, Romark Biosciences, LLC, and Romark Holdings, LLC.
• A judgment was entered on November 13, 2023, ordering Romark to pay $6,717,431.69, including a principal amount of $5,246,782 plus interest.
• Collection efforts are ongoing, but the company has been unable to identify assets of Romark, and multiple other creditors have filed claims.
• The company cannot guarantee a successful outcome in collecting the funds owed.

Stakeholder Impact

• Shareholders: Will receive a cash dividend of $0.075 per common share. The share repurchase program continues, potentially benefiting shareholders through reduced share count. Net income improvement is positive, but revenue decline and legal collection uncertainty could impact long-term value.
• Employees: Transition to a virtual headquarters for administrative operations may impact some employees, though the filing states it will "maintain the same level of service."
• Customers: The company aims to provide services in a "more competitive manner" with the virtual headquarters model. Concentration of revenue with a few major customers indicates strong relationships but also a dependency risk.
• Creditors: The increase in cash and management's belief in sufficient liquidity for the next twelve months are positive for creditors. The dividend payable creates a short-term liability.

Next Steps

• Continue efforts to collect the $6,717,431.69 judgment from Romark Global Pharma, LLC and affiliates.
• Await status update from PRIDCO regarding the extension of the Industrial Tax Exemption Grant (Act No. 73).
• Assess the impact of the OBBBA tax provisions, effective fiscal year ended October 31, 2027, on consolidated financial statements.
• Continue to expand markets by strengthening business development infrastructure and realigning business strategies.
• Pay the declared cash dividend of $0.075 per common share on or about March 20, 2026.

Key Dates

Recommendation

While the significant increase in net income and strong cash position are positive indicators, the overall revenue decline, persistent operational loss, and the uncertainty surrounding the collection of a substantial legal judgment warrant a cautious approach. The dividend provides some return, but the company faces macroeconomic headwinds and customer concentration risks. A 'hold' recommendation allows investors to monitor the company's ability to reverse revenue trends and successfully resolve the legal collection, while benefiting from the dividend.

Keywords

Pharma-Bio Serv, PBSV, consulting, pharmaceutical, biotechnology, medical devices, compliance, SEC filing, 10-Q, financial results, Puerto Rico, United States, Europe, tax grant, revenue, net income, cash dividend, share repurchase, legal proceedings